Mayinglong Pharmaceutical Group Co Ltd600993
▲ PositiveCapitalrelevance
Net profit up 5.65% and revenue up 3.22% in interim report.

Mayinglong released its 2026 interim report. Total operating revenue was 2.012 billion yuan, up 3.22% year on year, and net profit attributable to the parent company was 363 million yuan, up 5.65% year on year. Net cash inflow from operating activities was 430 million yuan, up 38.53% year on year. The company's asset-liability ratio was 20.61%, gross margin was 46.87%, return on equity was 8.17%, and diluted earnings per share was 0.84 yuan.
Mayinglong Pharmaceutical Group Co LtdNet profit up 5.65% and revenue up 3.22% in interim report.